AbbVie announced that SKYRIZI has been listed on public drug formularies in Ontario and Alberta for the treatment of moderately to severely active ulcerative colitis. The reimbursement access should support broader patient uptake in two Canadian provinces. This is a positive commercialization update for AbbVie, but the immediate market impact is likely limited.
AbbVie announced that SKYRIZI has been listed on public drug formularies in Ontario and Alberta for the treatment of moderately to severely active ulcerative colitis. The reimbursement access should support broader patient uptake in two Canadian provinces. This is a positive commercialization update for AbbVie, but the immediate market impact is likely limited.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
